Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
4.850
+0.040 (0.83%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Ardelyx Revenue
In the year 2024, Ardelyx had annual revenue of $333.62M with 168.06% growth. Ardelyx had revenue of $116.13M in the quarter ending December 31, 2024, with 237.95% growth.
Revenue (ttm)
$333.62M
Revenue Growth
+168.06%
P/S Ratio
3.42
Revenue / Employee
$844,595
Employees
395
Market Cap
1.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
ARDX News
- 6 days ago - Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 - GlobeNewsWire
- 13 days ago - Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings - GlobeNewsWire
- 23 days ago - Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - GlobeNewsWire
- 5 weeks ago - Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award - GlobeNewsWire
- 7 weeks ago - Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express + - Seeking Alpha
- 2 months ago - Tenapanor Approved in China for Hyperphosphatemia - GlobeNewsWire
- 2 months ago - Ardelyx to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade) - Seeking Alpha